MacroGenics Announces The Appointment Of Eric Risser As President And Chief Executive Officer, Strengthening Leadership Team

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapies for cancer, announced that Eric Risser has been appointed President, Chief Executive Officer, and a member of the Board of Directors, effective August 13, 2025.

Mr. Risser has been with MacroGenics since 2009, initially leading business development efforts and later assuming roles with increasing operational and strategic responsibility. Most recently, he served as Chief Operating Officer since 2022, overseeing key company functions and leading corporate development initiatives that have generated over $1.6 billion in non-dilutive capital since the company’s inception. He succeeds Scott Koenig, M.D., Ph.D., who is stepping down after serving as President and Chief Executive Officer for 24 years.

Bill Heiden, MacroGenics’ Chair, stated, Eric is a highly strategic leader who brings almost 30 years of biotech and pharmaceutical industry experience, with a track record of value creation, effective portfolio management and creative deal-making. Eric has a compelling vision for MacroGenics, and the Board and I are enthusiastic about helping bring it to life.”

He also added, “On behalf of Eric, the Board, the Company’s employees, and all of the individuals with whom Scott has worked tirelessly since the Company’s founding, I would like to extend our sincere gratitude to Scott for his many years of service. Under his leadership, the Company had many successes, including the development of three products which are now FDA-approved. The Company will continue to have access to Scott as Director and as an advisor.”

Mr. Risser mentioned, “I want to thank the Board for their confidence in my ability to lead MacroGenics into its next chapter. My goal is to create an even more focused and capital-efficient biotechnology company that delivers novel, high-value therapies to patients battling cancer. I will be working closely with the entire executive team and Board to ensure MacroGenics is investing resources where we believe we can generate significant value for both patients and shareholders alike.”

Before joining MacroGenics, Mr. Risser was Senior Director in Corporate Development at Johnson & Johnson, where he led multiple licensing and acquisition transactions. Earlier in his career, he held various roles in life sciences investment banking, venture capital, and strategy consulting. He holds an M.B.A. from Stanford University and a B.A. from Yale University.